May 2015: Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been granted rapid approval by the Food and Drug Administration. This approval is specifically for people with relapsed or ...
April 2024: Tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) has received formal approval from the Food and Drug Administration for the treatment of recurrent or metastatic cer...
Pancreatic cancer Pancreatic cancer, also referred to as the "king of cancers," is a highly deadly malignant tumor, with a survival rate of fewer than 10% over a 5-year period. As a result of inadequ...
Nogapendekin alfa inbakicept-pmln with BCG for bladder cancer There is a type of bladder cancer called NMIBC that does not spread to the muscles. The Food and Drug Administration has approved the use...
Alectinib approved in the treatment of non-small cell lung cancer The Food and Drug Administration (FDA) has approved the drug Alecensa, made by Genentech, Inc. It can be used as an extra treatment f...
Zevor-Cel therapy Chinese regulators have approved zevorcabtagene autoleucel (zevor-cel; CT053), an autologous CAR T-cell therapy, for the treatment of adult patients with multiple myeloma that has r...
Introduction In the ever-evolving realm of oncological treatment, scientists persistently seek out unconventional targets that can amplify the effectiveness of interventions while mitigating unwanted...
Introduction Even in transplant-eligible (TE) patients, typical first-line treatments for high-risk (HR) newly-diagnosed multiple myeloma (NDMM) have dismal outcomes. A high-efficacy, safe CAR-T trea...
Introduction CAR T cell therapy, an innovative form of immunotherapy, has demonstrated exceptional efficacy in the treatment of specific tumors by leveraging the potency of a patient's own immune sys...
March 2024: The Food and Drug Administration has granted approval for mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) to be used in adult patients with FRα positive, ...